ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension (ACES)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03295734 |
Recruitment Status :
Recruiting
First Posted : September 28, 2017
Last Update Posted : May 12, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension Aging Sedentary Lifestyle | Behavioral: Aerobic exercise Drug: Perindopril Drug: Losartan Drug: HCTZ | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 213 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension |
Actual Study Start Date : | May 29, 2018 |
Estimated Primary Completion Date : | September 2023 |
Estimated Study Completion Date : | September 2023 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Perindopril
4 mg qd titrated to 8 mg qd perindopril + aerobic exercise
|
Behavioral: Aerobic exercise
Twice weekly centered based aerobic exercise + 3/week home-based walking Drug: Perindopril 4 mg qd titrated to 8 mg qd perindopril |
Active Comparator: Losartan
50 mg qd titrated to 100 mg qd losartan + aerobic exercise
|
Behavioral: Aerobic exercise
Twice weekly centered based aerobic exercise + 3/week home-based walking Drug: Losartan 50 mg qd titrated to 100 qd losartan |
Active Comparator: HCTZ
12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise
|
Behavioral: Aerobic exercise
Twice weekly centered based aerobic exercise + 3/week home-based walking Drug: HCTZ 12.5 mg qd titrated to 25 qd HCTZ |
- Gait speed [ Time Frame: 32 weeks ]Self-paced gait speed over 4m distance
- Six minute walk test [ Time Frame: 32 weeks ]maximal distance covered over six minutes
- Body composition [ Time Frame: 32 weeks ]% body fat/lean mass collected via dual x-ray absorptiometry
- Circulating indices of cardiovascular risk [ Time Frame: 32 weeks ]TNF-α, IL-6, VCAM-1, E-selectin; oxidized LDL; myeloperoxidase

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 60 years and older
- Hypertension - untreated (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) or treated
- > 290 seconds needed to complete long-distance corridor walk test
- Sedentary lifestyle, defined as <150 min/wk of moderate physical activity
- Willingness to participate in all study procedures, including allowing study team to communicate with primary care physician regarding changes in antihypertensive treatment
Exclusion Criteria:
- BP > 140/90, despite the use of three or more anti-hypertensive drugs
- SBP > 180 mm Hg or DBP > 110 mm Hg
- Chronic kidney disease
- Serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women
- Serum potassium outside normal reference range
- Urinary protein > 1 on dipstick
- Abnormal liver enzymes (AST, ALT, or alkaline phosphatase > 2.5 times the upper limit of normal)
- Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
- Acute myocardial infarction identified by ECG
- Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination exam score < 24;
- Simultaneous participation in another intervention trial
- Known hypersensitivity to ACE inhibitors (exclusion only to perindopril arm; will be randomized among other two interventions)
- Any other condition that would preclude participating based upon judgement of PI or study clinician team

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03295734
Contact: Thomas Buford, PhD | 2059963008 | twbuford@uabmc.edu |
United States, Alabama | |
UAB Center for Exercise Medicine | Recruiting |
Birmingham, Alabama, United States, 35205 | |
Contact: Kate Connor, PhD 205-996-3005 connork@uab.edu | |
United States, Colorado | |
University of Colorado Medical Center | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Zachary Buxo ZACHARY.BUXO@CUANSCHUTZ.EDU | |
United States, Florida | |
Translational Research Institute | Recruiting |
Orlando, Florida, United States, 32804 | |
Contact: Susann Nagel Susann.Buller@AdventHealth.com |
Principal Investigator: | Thomas Buford, PhD | University of Alabama at Birmingham | |
Principal Investigator: | Wendy Kohrt, PhD | University of Colorado, Denver | |
Principal Investigator: | Bret Goodpaster, PhD | Translational Research Institute, Advent Health |
Responsible Party: | Thomas W. Buford, Associate Professor, University of Alabama at Birmingham |
ClinicalTrials.gov Identifier: | NCT03295734 |
First Posted: | September 28, 2017 Key Record Dates |
Last Update Posted: | May 12, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Hypertension Vascular Diseases Cardiovascular Diseases Losartan Perindopril Anti-Arrhythmia Agents Antihypertensive Agents |
Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Angiotensin-Converting Enzyme Inhibitors Protease Inhibitors Enzyme Inhibitors |